[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allogeneic-blood-and-marrow-transplantation-bmt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allogeneic-blood-and-marrow-transplantation-bmt":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100615167",false,"NCT07289087","Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy","A Real-World Observational Study on Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation (Allo-SCT) and CAR-T Therapy","QOL-ONE PRO-CT","Inclusion Criteria:\n\n* Diagnosed with a hematologic malignancy (e.g., leukemia, lymphoma, multiple myeloma)\n* Undergoing either allogeneic SCT or CAR-T therapy\n* Able and willing to provide written informed consent\n* Sufficient Italian proficiency to complete the HM-PRO\n* Signed informed consent\n\nExclusion Criteria:\n\n* Cognitive or physical impairments that preclude the ability to complete questionnaires\n* Estimated life expectancy \\\u003C 7 days at the time of admission","ALL","18 Years",{"count":19,"type":20},162,"ESTIMATED","OBSERVATIONAL","3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).",[24,25,26,27],"Quality of Life","Patient Reported Outcome (PRO)","Allogeneic Blood and Marrow Transplantation (BMT)","CAR T Cell Therapy",[24,29,30,31,32,33,34],"CAR-T cell therapy","Allogenic BMT","Patient Reported Outcome","Leukemia","Multiple Myeloma","Lymphoma","NOT_YET_RECRUITING","2025-12-04",{"date":38,"type":39},"2025-12-17","ACTUAL",{"date":41,"type":20},"2026-02-15",{"date":43,"type":20},"2027-04-01",{"name":45,"class":46},"Associazione Qol-one","OTHER",""]